Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
PACTO trial: what clinicians have said so far
Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients
- NCT02767557 ↗
- Completed
- Herlev Hospital
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on PACTO yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PACTO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Unresectable Pancreatic Carcinoma
- Interventions
- Tocilizumab; Gemcitabine; nab-Paclitaxel
- Arms
- Tocilizumab & Gemcitabine and nab-Paclitaxel · Experimental
- Gemcitabine and nab-Paclitaxel · Active comparator
- Enrollment
- 147
- Primary outcomes
- Overall survival at 6 months
- Sponsor
- Herlev Hospital with Celgene
- Start
- Jan 26, 2017
- Primary completion
- Aug 12, 2021
- Results posted
- No
- Registry record
- NCT02767557 · updated Sep 22, 2023
Publications
linked from the registry- Kjaer LK, Theile S, Madsen K, Johansen JS, Holmstrom MO, Andersen MH, Chen IM. Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. Immun Inflamm Dis. 2026 Oct;14(10):e70545. doi: 10.1002/iid3.70545. PubMed 42836590
- Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. J Clin Oncol. 2025 Jun 20;43(18):2107-2118. doi: 10.1200/JCO.23.01965. Epub 2025 May 12. PubMed 40354592